Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Real-Time PCR Test Identifies Aspergillus

By LabMedica International staff writers
Posted on 07 Dec 2009
A new test has been launched to assist medical and scientific professionals to identify Aspergillus, one of the most common causes of fungal pneumonia.

MycAssay Aspergillus is a real-time polymerase chain reaction (RT-PCR) test that accurately and rapidly identifies infections caused by Aspergillus.

Pneumonia caused by Aspergillus is the leading cause of infectious death in leukemia and bone marrow patients with an estimated 10 million people at risk globally each year. More...
Diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90% to 40% highlighting the necessity of early, rapid diagnostic testing.

Myconostica (London, UK), a medical diagnostic company specializing in rapid molecular diagnostic tests for life-threatening fungal infections, launched the MycAssay Aspergillus test, which has gained CE marking.

Traditional methods used to identify Aspergillus infections are inaccurate, insensitive, and slow, with a result taking up to 10 days to obtain. When MycAssay Aspergillus is combined with Myconostica´s fungal DNA extraction system, MycXtra, a result can be obtained within 3 hours. This provides a rapid, sensitive, and specific alternative to the conventional techniques used to identify Aspergillus infections.

Related Links:

Myconostica



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.